Results 71 to 80 of about 7,074,857 (310)

Metastatic niche shaped by host factors influences disseminated cancer cell fate

open access: yesFEBS Letters, EarlyView.
Metastasis is shaped not only by cancer cells but also by the environments they encounter. This review explores how factors such as aging, diet, the microbiome, lifestyle, and environmental exposures remodel organ‐specific niches in the lung, liver, bone, and brain, influencing where metastatic cells survive, remain dormant, or grow, and ultimately ...
Gwennan Delyth Ward   +2 more
wiley   +1 more source

Smaller is better: nanobodies meet NMR

open access: yesFEBS Letters, EarlyView.
Nanobodies are single‐domain antigen‐binding fragments derived from camelid heavy chain antibodies. Their small size, high stability, and exceptional specificity make nanobodies uniquely useful probes for NMR studies of protein dynamics, transient conformational states, and protein–protein interactions.
Oleg Y. Dmitriev
wiley   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

open access: yesMolecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla   +9 more
wiley   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Issued by the National Blood Users Group

open access: yes, 2002
Rapid and continuing loss of blood is life-threatening. Ensuring that tissue oxygenation is maintained at a level consistent with avoidance of critical ischaemic organ damage and irreversible organ failure demands speed and skill.
National Blood Users Group
core  

Epidemiological and Clinical Study of Phenylketonuria (PKU) Disease in the National Screening Program of Neonates, Fars Province, Southern Iran

open access: yesIranian Journal of Public Health, 2009
Background: Classic phenylketonuria (PKU) is a rare metabolic disorder that results from a deficiency of a liver enzyme known as phenylalanine hydroxylase (PAH).
S Senemar   +5 more
doaj  

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

open access: yesMolecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder   +10 more
wiley   +1 more source

A guideline for transfusion of red blood cells in surgical patients

open access: yes, 2000
Blood transfusion carries a real but unquantifiable risk of adverse outcome in surgical patients from infectious, immunological and cardiorespiratory morbid events.
National Blood Users Group
core  

Spectrum of Isolates and Antimicrobial Susceptibility Pattern from Blood Cultures in Tertiary Care Hospital, Riyadh

open access: yesJournal of Pure and Applied Microbiology
Clinical presentation of bloodstream infection ranges from transitory bacteremia to fulminant septic shock with substantial mortality. Regular monitoring of bacteremia etiology helps rationalize therapy, revealing the spectrum of bacterial infections and
Fizza Khalid   +4 more
doaj   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

open access: yesMolecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy